[
    [
        {
            "time": "2018-03-15",
            "original_text": "Nordisk's Dichotomy Abounds",
            "features": {
                "keywords": [
                    "Nordisk",
                    "Dichotomy",
                    "Abounds"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Nordisk's Dichotomy Abounds",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill",
            "features": {
                "keywords": [
                    "diabetes",
                    "Novo",
                    "Nordisk",
                    "new pill"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-10",
            "original_text": "Analysts’ Recommendations for Novartis after Its 4Q17 Earnings",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "Novartis",
                    "4Q17",
                    "Earnings"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for Novartis after Its 4Q17 Earnings",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]